Javier Perez Stachowski

Dr. Javier Perez Stachowski

Hospital Costa del Sol, Marbella, Andalusia, Spain
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JOJulian Olalla-Sierra
Julian Olalla-Sierra
JLJose María García de Lomas
Jose María García de Lomas
EMEfrén Márquez
Efrén Márquez
FGFrancisco Jesús González
Francisco Jesús González
AJAlfonso Del Arco Jiménez
Alfonso Del Arco Jiménez
JGJavier García-Alegría
Javier García-Alegría
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The elderly HIV patient population not only presents more comorbidity and poly-medication, but also suffers from stigmatization on behalf of society and lack of social support, where new technologies can now play a role towards enhancing the empowerment of these patients. Objective: To encourage a greater knowledge about the infection, promote patient treatment adherence and offer them the possibility of anonymously establishing contact between them and their peers. Methods: A series of clinical and psychosocial parameters were studied in 30 HIV-infected patients of over 60 years of age. 15 of them were randomized to use an app and 15 were the control group. All tests were repeated after 6 months. Results: The median age of patients was 66,5 years old, with an 11-year period suffering from HIV infection. 29 of them had an undetectable viral load and CD4 nadir was 194 cel/micromole. Median number of comorbidity diseases was 2. 11 of them lived with their parents and 19 lived alone. They spent an average of 5 hours a day sitting down and 56,7% of them referred high physical activity. They scored 4 out of 5 for general quality of life perception. 80% presented high adherence to their treatment and average number of concomitant medication was 5. In the 6-minute walking test (6MWT) they covered a distance of 400 meters and 3 of them desaturated during the test. The 15 patients made frequent use of the app with 2407 sessions and an average of 7 minutes and 56 seconds time of use with a total of 13143 screen views. During the 6 months of the trial, 3 non-AIDS events took place. There were no significant modifications to BMI, blood pressure measurements, lipid profile or panel or immuno-virology information data. Neither was there any significant modification in the distance covered in the 6MWT or of the desaturation percentage. There wasn´t any differences in the questionnaire scores for perception of quality of life either, or for confessed physical activity or ART and non-ART treatment adherence. Conclusions: Significant differences between studied parameters were not objectified in these patients, although this trial has a small sample size and only a brief follow-up period is considered. However, patients did make a frequent use of the app, making this a possible method of intervention to be proposed in future subsequent studies

20 May 2017 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
SGSandra M. Gómez-Espejo
Sandra M. Gómez-Espejo
JOJulián Olalla-Sierra
Julián Olalla-Sierra
PMPilar Marí-Jiménez
Pilar Marí-Jiménez
TPTeresa Pereda-Salguero
Teresa Pereda-Salguero
JSJavier Perez Stachowski
Javier Perez Stachowski
JPJosé L. Prada-Pardal
José L. Prada-Pardal

10 October 2018 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
JOJulian Olalla-Sierra
Julian Olalla-Sierra
JSJavier Perez Stachowski
Javier Perez Stachowski
BTBegoña Tortajada
Begoña Tortajada
AJAlfonso Del Arco Jiménez
Alfonso Del Arco Jiménez
EMEfrén Márquez
Efrén Márquez
JGJavier García-Alegría
Javier García-Alegría
Background: Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. Methods: Between February and June 2017, switch from Triumeq® to a generic pharmaceutical specialty co-formulated tablet (abacavir + lamivudine) plus Tivicay® was made. Demographic, viroimmunological characteristics and the Charlson index were collected. Six months after switching, efficacy and safety were evaluated. Results: Switch was made in 93 patients, with a mean age of 47 years, after six months there were five patients (5.4%) with viral loads between 50 and 400 copies, no patient had viral loads of greater amount. There were 2 interruptions due to toxicity (2.15%), in relation to symptoms of the central nervous system. There were no differences in the amount of years with HAART, nor in the previous months with the STR regimen based on abacavir + lamivudine + dolutegravir, nor in the Charlson index. The effective saving in 2017 derived from the change in these 93 patients was € 125.512. Conclusions: The change from a regimen of abacavir + lamivudine + dolutegravir seems to be safe and effective at 24 weeks.

10 May 2015 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
JOJulian Olalla-Sierra
Julian Olalla-Sierra
ECElena Crespo
Elena Crespo
JTJavier de la Torre-Lima
Javier de la Torre-Lima
MSMarco Sempere
Marco Sempere
AJAlfonso Del Arco Jiménez
Alfonso Del Arco Jiménez
JGJavier García-Alegría
Javier García-Alegría
To determine the levels of NT-pro BNP in HIV patients over 40 years who are receiving highly active antiretroviral therapy (HAART) and investigating potential independent clinical or laboratory factors. We determine levels of NT-pro BNP in peripheral blood of HIV patients from Costa del Sol Hospital, over 40 years. We collected epidemiological, classical cardiovascular risk factors and variables associated with HIV infection status. The qualitative variables were compared using the χ2 test. NT-proBNP levels were taken as the dependent variable. The association between these levels and the quantitative variables were studied by analysis of variance (ANOVA), and the association with the qualitative variables, using Student’s t test. Nt-pro BNP levels were determined in 146 HIV patients. We assess the 10-year cardiovascular risk calculated by the Framingham equation, 59 (41.5%) were classified as low risk, 46 (32.4%) as a moderate risk and 37 (26.1%) as a high risk. The higher levels of NT-pro BNP were found in women, and in those patient with lower filtration rate and high levels of triglycerides. An association was also observed between higher levels of NT-proBNP and the recent use of lamivudine and fosamprenavir. After a multivariate analysis we found an association between higher levels of NT-proBNP and the current use of fosamprenavir and a lower glomerular filtration rate. We found, with the limitations of a small serie, that higher levels of NTproBNP in HIV patients could be linked to the occurrence of cardiovascular events, this fact suggest that NTpro BNP could be used in patients at moderate or high vascular risk in order to optimise the primary prevention of vascular events.

27 October 2016 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
O(on behalf of the HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
on behalf of the HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Antonio Rivero-JuarezAntonio Rivero-Juarez
Antonio Rivero-Juarez
LCLuis Fernando Lopez Cortes
Luis Fernando Lopez Cortes
MCM. Castaño
M. Castaño
DMD. Merino
D. Merino
Antonio Rivero-JuarezAntonio Rivero-Juarez
Antonio Rivero-Juarez
In April 2015, the Spanish National Health System (SNHS) developed a national strategic plan for the diagnosis, treatment, and management of hepatitis C virus (HCV). Our aim was to analyze the impact of this on human immunodeficiency virus (HIV)-infected patients included in the HERACLES cohort during the first 6 months of its implementation. The HERACLES cohort (NCT02511496) was set up in March 2015 to evaluate the status and follow-up of chronic HCV infection in patients co-infected with HIV in the south of Spain. In September 2015, the data were analyzed to identify clinical events (death, liver decompensation, and liver fibrosis progression) and rate of treatment implementation in this population. The study population comprised a total of 3474 HIV/HCV co-infected patients. The distribution according to liver fibrosis stage was: 1152 F0–F1 (33.2 %); 513 F2 (14.4 %); 641 F3 (18.2 %); 761 F4 (21.9 %); and 407 whose liver fibrosis was not measured (12.3 %). During follow-up, 248 patients progressed by at least one fibrosis stage [7.1 %; 95 % confidence interval (CI): 6.3–8 %]. Among cirrhotic patients, 52 (6.8 %; 95 % CI: 5.2–8.9 %) developed hepatic decompensation. In the overall population, 50 patients died (1.4 %; 95 % CI: 1.1–1.9 %). Eight hundred and nineteen patients (23.56 %) initiated interferon (IFN)-free treatment during follow-up, of which 47.8 % were cirrhotic. In our study, during 6 months of follow-up, 23.56 % of HIV/HCV co-infected patients included in our cohort received HCV treatment. However, we observed a high incidence of negative short-term outcomes in our population.

22 April 2019 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
Antonio Rivero-JuarezAntonio Rivero-Juarez
Antonio Rivero-Juarez
FTF Tellez
F Tellez
MCM Castaño‐Carracedo
M Castaño‐Carracedo
DMD Merino
D Merino
NEN Espinosa
N Espinosa
T(The Grupo de Estudio de Hepatitis Virales (Hepavir) Of The Sociedad Andaluza de Enfermedades Infecciosas (Saei)
The Grupo de Estudio de Hepatitis Virales (Hepavir) Of The Sociedad Andaluza de Enfermedades Infecciosas (Saei)